Clinical Trial

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Trial Details
NCT Number NCT07246707
Lead Sponsor Zhejiang University
Collaborators: TCRx Therapeutics Co.Ltd
Conditions B-ALL
Enrollment 30 participants
Start Date 2026-01-02
Primary Completion 2027-10 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-17